Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses PDL1 as a biomarker for first line.
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full...
Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?
Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment.
Don't Miss Out! the newest GRACE Newsletter is out now! Keep Moving Forward - GRACE in January is full of the newest information about the Global...
Support and the Caregiver Caring for a Caregiver When test reports come in, and the building anticipation confirms the worst fears with a diagnosis of...
Hi, my name is Hannah, I am 25 year old female, who has always been healthy. I am just looking for some help. I am desperate for answers, as I have...
Good afternoon all, I feel terrible for writing this, especially when there are so many of you bravely fighting this. I started experiencing horrific...
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for first-line treatment.
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy combined.
Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy with chemotherapy.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses the role for immunotherapy in patients with a driver mutation.
Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses Liquid Biopsies for Broad Genomic Testing in Lung Cancer.
Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses liquid biopsies for EGFR T790 non-small cell lung cancer (NSCLC).
Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses the changing landscape of first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC).
Download slides from LIVE WEBCAST of November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know
GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de inducción preferida?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple).
Transcription:
¿Hay alguna terapia de inducción preferida?
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC).
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.